Header Logo

Connection

JOSEPH JANKOVIC to Neuroprotective Agents

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Neuroprotective Agents.
JOSEPH JANKOVIC
Connection Strength
3.594
Neuroprotective Agents
  1. The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015 Mar; 30(3):313-27.
    View in: PubMed
    Score: 0.418
  2. Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord. 2014 Jun; 20(6):640-3.
    View in: PubMed
    Score: 0.392
  3. Advances in the pharmacological management of Huntington's disease. Drugs. 2010 Mar 26; 70(5):561-71.
    View in: PubMed
    Score: 0.298
  4. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):70-3.
    View in: PubMed
    Score: 0.287
  5. Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges. Pharmacol Res. 2025 Jun; 216:107770.
    View in: PubMed
    Score: 0.213
  6. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord. 2005; 20 Suppl 11:S3-10.
    View in: PubMed
    Score: 0.208
  7. Neuroprotection in Parkinson disease. Arch Intern Med. 2003 Jul 28; 163(14):1650-4.
    View in: PubMed
    Score: 0.188
  8. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol. 2003 Jan-Feb; 26(1):18-23.
    View in: PubMed
    Score: 0.181
  9. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002 Mar; 8(4):271-6.
    View in: PubMed
    Score: 0.171
  10. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001; 18(6):389-96.
    View in: PubMed
    Score: 0.157
  11. New and emerging therapies for Parkinson disease. Arch Neurol. 1999 Jul; 56(7):785-90.
    View in: PubMed
    Score: 0.142
  12. Neuroprotection by Orexin-A via HIF-1a induction in a cellular model of Parkinson's disease. Neurosci Lett. 2014 Sep 05; 579:35-40.
    View in: PubMed
    Score: 0.101
  13. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm (Vienna). 2011 Mar; 118(3):473-7.
    View in: PubMed
    Score: 0.078
  14. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct; 57(3):198-205.
    View in: PubMed
    Score: 0.076
  15. Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience. 2009 Dec 01; 164(2):541-51.
    View in: PubMed
    Score: 0.071
  16. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008 Nov 15; 23(15):2194-201.
    View in: PubMed
    Score: 0.068
  17. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis. 2008 Oct; 32(1):16-25.
    View in: PubMed
    Score: 0.066
  18. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem. 2008 Jun; 105(5):1970-8.
    View in: PubMed
    Score: 0.065
  19. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006 Mar 14; 66(5):672-7.
    View in: PubMed
    Score: 0.056
  20. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett. 2005 Dec 19; 579(30):6716-20.
    View in: PubMed
    Score: 0.055
  21. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neurosci Lett. 2005 Mar 29; 377(2):106-9.
    View in: PubMed
    Score: 0.053
  22. Dopamine agonists in Parkinson's disease. Expert Opin Investig Drugs. 2003 Nov; 12(11):1803-20.
    View in: PubMed
    Score: 0.048
  23. Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging. 2003; 20(10):711-21.
    View in: PubMed
    Score: 0.045
  24. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000 Mar 10; 281(2-3):167-70.
    View in: PubMed
    Score: 0.037
  25. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm (Vienna). 2000; 107(10):1165-73.
    View in: PubMed
    Score: 0.037
  26. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 1999; 64(15):1275-85.
    View in: PubMed
    Score: 0.034
  27. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J Neurochem. 2010 Oct; 115(1):188-99.
    View in: PubMed
    Score: 0.019
  28. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24; 361(13):1268-78.
    View in: PubMed
    Score: 0.018
  29. Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury. Life Sci. 2003 Jan 17; 72(9):1073-83.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.